JESSICA GAGNON: Open Payments
NPI 1184064214 · CORPUS CHRISTI, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,781 in 81 payments from 15 companies in 2025. Trend: 2023 $2,605 · 2024 $1,899 · 2025 $1,781
Food & beverage: $1,781
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 16 | $333 |
| Medtronic, Inc. | 8 | $318 |
| Novo Nordisk Inc | 10 | $184 |
| GlaxoSmithKline, LLC. | 16 | $157 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $142 |
| Amgen Inc. | 12 | $139 |
| Otsuka America Pharmaceutical, Inc. | 1 | $122 |
| Verona Pharma, Inc. | 1 | $117 |
| AstraZeneca Pharmaceuticals LP | 4 | $71 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $45 |
Products named: SYNCHROMEDII, MOUNJARO, TRELEGY ELLIPTA, REXULTI, Ozempic, KISUNLA, Ohtuvayre, OTEZLA.
Industry payments across TX — which companies pay providers there.
